| 영문 | bone marrow | 한글 | 골수 |
|---|---|---|---|
| 설명 | 혈구세포를 생성하는 장소를 이르는 말. 어린이에 있어서는 모든 뼈에 골수가 존재하지만 어른이 되면 대개 긴뼈의 내부나 납작뼈의 내부에만 존재한다. 혈구를 왕성하게 생성을 하는 골수는 적색을 띠게 되므로 이것을 적색골수라고 한다. 혈액을 생성하지 않는 골수의 경우는 그곳에 지방질의 침착이 있어서 황색으로 변색되므로 이곳을 황색골수라고 한다. 어른에 있어서는 몇몇의 뼈를 제외하고 거의 전부가 적색골수가 황색골수로 대치되어 있다. |
||
| 영문 | bone marrow biopsy | 한글 | 골수생검 |
|---|---|---|---|
| 설명 | 골수를 진단이나 병에 의한 변화를 알기위해서 채취하는 것. |
||
| 영문 | bone marrow transplantation | 한글 | 골수이식 |
|---|---|---|---|
| 설명 | 환자의 병든 골수 대신 건강한 골수세포를 이식하는 처치-암치료에 방사선요법이나 화학요법을 썼을 경우 그 부작용으로 골수의 기능이 극도로 나빠졌을 때나 또는 백혈병의 경우에 면역요법으로 이용된다. 방법은 건강한 골수액을 채취하여 인산완충액을 섞은 링거액에 부유시켜 여과한 다음 정맥에 주사한다. 주입한 골수가 체내에 착상하여 번식하기 쉽게 할 목적으로 미리 X선을 조사하여 이식받는 환자의 항체기능을 억제해 둘 필요가 있다. 이 조작은 급성 방사능증을 일으키기 때문에 여러 가지 보호치료가 필요하다. 그러나 골수를 이식하면 급성 방사능증을 가볍게 넘길 수 있다고 하여 반대로 방사능을 대량으로 조사받은 사람에게 그 치료법으로 이용되기도 한다. 이식에는 스스로의 골수세포를 미리 채취해 놓고 후에 자신에게 주입하는 자가이식과 일란성쌍둥이의 한쪽에서 골수세포를 주입하는 동계이식 및 조직적합항원이 일치한 타인의 골수세포를 주입하는 동종이식이 있다. 대상병으로 백혈병, 재생불량빈혈, 선천면역결핍증 등이 있다. 일반적으로 강력한 면역억제제의 투여가 필요하다. 부작용으로서는 골수이식 후 이식편대숙주병, 기회감염 등이 있다. |
||
| 영문 | red bone marrow | 한글 | 적색골수 |
|---|---|---|---|
| 설명 | 분화중의 갈비뼈, 척추뼈나 그 외의 많은 작은 뼈에 있는 활동성 골수이다. 적혈구나 과립백혈구의 생산 장소이다. |
||
| 영문 | muscle cell(=muscle fiber) | 한글 | 근육세포 |
|---|---|---|---|
| 설명 | 근육은 수의근(의식에 의해서 조절이 가능한 근육: 예를 들어 다리, 팔, 얼굴근육 등)과 불수의근(의식과 무관하게 조절하지 않아도 움직이는 근육: 예를 들어 심장근, 소화기관에 분포하는 근육 등)으로 나누어지며, 근육세포의 모양은 다음과 같다(수의근, 불수의근 외에 심장에 있는 심장근은 불수의근에 해당하지만 그 모양은 수의근과 같아 따로 분류한다).  |
||
| MBLA | methylbenzyl linoleic acid; mouse-specific bone-marrow-derived lymphocyte antigen |
|---|---|
| TCE | T-cell enriched; tetrachlorodiphenyl ethane; trichloroethylene T-cell thymus-derived cell |
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
| BMC | blood mononuclear cell; bone marrow cell; bone mineral content |
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
| MBMMC | mouse bone marrow derived mast cell |
|---|---|
| BMM | Bone marrow-derived macrophages |
| BMMC | Bone marrow-derived mast cells |
| BMDM | bone marrow-derived macrophage |
| BMM phi | bone marrow-derived mononuclear phagocytes |
| marrow cell | Any cell of bone marrow, especially haemopoietic cell's. (05 Mar 2000) |
|---|---|
| brain-derived growth factor | <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3. In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF. In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. Acronym: BDGF (12 Dec 1998) |
| brain-derived neurotrophic factor | <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3. In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF. In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. Acronym: BDGF (12 Dec 1998) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| refuse-derived fuel | (RDF) Fuel prepared from municipal solid waste. Noncombustible materials such as rocks, glass, and metals are removed, and the remaining combustible portion of the solid waste is choped or shreaded. RDF facilities process between 100 and 3000 tons of MSW per day. (05 Dec 1998) |
| monocyte derived neutrophil chemotactic factor | <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes. It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4. Acronym: IL-8 (12 Dec 1998) |
| platelet-derived growth factor | <growth factor> The major mitogen in serum for growth in culture of cells of connective tissue origin. It consists of 2 different but homologous polypeptides A and B (~30,000 D) linked by disulphide bonds. Believed to play a role in wound healing. It is carried in the alpha-granules of platelets and is released when platelets adhere to traumatised tissues. Connective tissue cells near the traumatised region respond by initiating the process of replication. The B chain is almost identical in sequence to p28sis, the transforming protein of simian sarcoma virus, that can transform only those cells that express receptors for platelet derived growth factor, suggesting that transformation is caused by autocrine stimulation. The receptor is a tyrosine kinase. Acronym: PDGF (12 Dec 1998) |
| schwannoma derived growth factor | <growth factor> A growth factor containing an EGF like domain, mitogenic for astrocytes, Schwann cells and fibroblasts. (18 Nov 1997) |
| derived protein | A derivative of protein effected by chemical change, e.g., hydrolysis. (05 Mar 2000) |
| oxygen derived free radicals | An atom or atom group having an unpaired electron on an oxygen atom, typically derived from molecular oxygen. For example, one-electron reduction of O2 produces the superoxide radical, O2-; other examples include the hydroperoxyl radical (HOO-), the hydroxyl radical (HO-), and nitric oxide (NO-). (05 Mar 2000) |
| thymus derived lymphocyte | <haematology, immunology> A class of lymphocytes, so called because they are derived from the thymus and have been through thymic processing. Involved primarily in controlling cell-mediated immune reactions and in the control of B-cell development. The T-cells coordinate the immune system by secreting lymphokine hormones. There are 3 fundamentally different types of t cells : helper, killer, and suppressor. Each has many subdivisions. T-cells are also called t lymphocytes. They bear T-cell antigen receptors (CD3) and lack Fc or C3b receptors. Major T-cell subsets are CD4 (mainly helper cells) and CD8 (mostly cytotoxic or suppressor T-cells). Uncontrolled proliferation of this type of cell gives rise to T-cell leukaemia/lymphoma. (21 Jun 1999) |
| endothelium-derived growth factor synthase | <enzyme> Converts l-arginine to a smooth muscle relaxing factor and stimulates the formation of cyclic-GMP Registry number: EC 1.5.1.- Synonym: edrf synthase (26 Jun 1999) |
| endothelium derived relaxation factor | <biochemistry> This compound is produced from L arginine by the enzyme nitric oxide synthase. Acts as a potent vasorelaxant via elevation of intracellular cGMP in vascular smooth muscle. Synthesis of nitric oxide is not confined to endothelium, isoforms of nitric oxide synthase are also found in brain, neutrophils and platelets. Synonym: endothelium derived relaxation factor. Acronym: NO (29 Dec 1997) |
| endothelium-derived relaxing factor | A labile humoral agent released by the vascular endothelium that mediates the relaxation induced by some vasodilators such as acetylcholine and bradykinin. Edrf also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. These actions are believed to be mediated through stimulation of guanylate cyclase and the consequent elevation of cyclic guanosine 3',5'-monophosphate. Edrf is thought to be nitric oxide or a ready source of it. The factor is believed to be unstable and acts only locally in vivo. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|